Investigating a new antiviral drug that targets HIV-1 in a unique way
Characterization of JT-4-173, a Potent Antiviral that Inhibits HIV-1 by a Novel Mechanism of Action
This study is testing a new antiviral drug called JT-4-173 that aims to help people living with HIV-1 by targeting a specific part of the virus, which could lead to better treatment results and fewer side effects than current options.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10892074 on NIH RePORTER |
What this research studies
This research focuses on developing JT-4-173, a novel antiviral drug designed to inhibit HIV-1 by targeting a specific site on the virus's reverse transcriptase enzyme. The approach aims to overcome the limitations of current treatments, particularly drug resistance associated with existing antiretroviral therapies. By exploring the binding properties of JT-4-173, the research seeks to provide a new therapeutic option for individuals living with HIV-1. Patients may benefit from improved treatment outcomes and potentially fewer side effects compared to traditional therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who may be experiencing challenges with current antiretroviral treatments.
Not a fit: Patients who are not infected with HIV-1 or those who have already achieved viral suppression with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new class of antiviral drugs that effectively manage HIV-1 infection and reduce the reliance on current therapies.
How similar studies have performed: Previous research has shown promise in developing novel antiviral agents targeting different mechanisms of HIV-1, indicating potential for success with this new approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Wen, Xin — Emory University
- Study coordinator: Wen, Xin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.